Power and sample size: a study might be too small to detect a real effect (low power). Sample size calculations help determine how many participants are needed to detect an effect of a given magnitude.
Sample size intuition for a personal experiment — does this still hold? posts 31–39
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Coming back to post #30, because the follow-up matters more than the original answer.
Effect sizes: the magnitude of a difference, not just whether it is statistically significant. A difference that is significant (p<0.05) might be too small to matter. A large effect might not be significant if sample size is small.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
Confounding: a third variable explains an apparent association. In randomised data, randomisation balances confounders. In observational data, confounders can be adjusted for but unknown ones cannot.
post #36 is right about the mechanism and I think understates the practical bit.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Worth separating two things that post #34 runs together.
Regression to the mean: if you select people with extreme values (very high or very low), their next measurement is often less extreme just by chance. This can look like a treatment effect when it is just statistics.
Confidence intervals: rather than a single point estimate, a range of plausible values. A narrow interval means precise measurement; a wide interval means measurement is imprecise. Wider intervals (more uncertainty) are honest about limitation.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
[2026 update] Correlation in a self-tracked dataset: what it can support
Posting this under the heading it deserves: Correlation in a self-tracked dataset: what it can support Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in support of a…
|
2 | 31k | 6h | |
|
Measurement error in home scales, with a worked standard deviation
Measurement error in home scales, with a worked standard deviation Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021) with STEP 1 ( N Engl…
|
+26 | 31 | 4.3k | 4mo |
|
Sample size intuition for a personal experiment
On the subject in the title: Sample size intuition for a personal experiment Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the discussion is…
|
4 | 62k | 18mo | |
|
Second pass at: Multiplicity when you track fifteen variables
Posting this under the heading it deserves: Second pass at: Multiplicity when you track fifteen variables Everything below is what sits behind that. I have seen SCALE ( N Engl J Med , 2015) cited in support…
|
2 | 12k | 18mo | |
|
Regression to the mean in progress reports
On the subject in the title: Regression to the mean in progress reports Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before posting; the discussion…
|
+30 | 34 | 49k | 12mo |
Related topics — sharing the tags effect size, heterogeneity, number needed to treat
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: the retatrutide phase 2 obesity paper
Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
|
+7 | 11 | 33k | 7mo |
|
Reverse causation in a cohort study of weight and outcome
On the subject in the title: Reverse causation in a cohort study of weight and outcome Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with FLOW ( N Engl J Med , 2024) and…
|
+10 | 14 | 11k | 7mo |
|
Journal club: the CagriSema phase 2 combination paper — a second dataset
Journal club: the CagriSema phase 2 combination paper — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a…
|
+74 | 79 | 2.3k | 13mo |
|
Pooling trials with different estimands
On the subject in the title: Pooling trials with different estimands Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and finding the…
|
+120 | 132 | 2.3k | 1d |
|
Follow-up: Individual participant data versus aggregate data
Individual participant data versus aggregate data — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURPASS-4 ( Lancet , 2021) and finding the…
|
+101 | 111 | 23k | 18mo |